10-K: Indivior PLC Navigates Opioid Crisis with Focus on SUBLOCADE, Faces Legal and Competitive Challenges

Sentiment:

Annual Report 3 March 2025 4:35 PM

Indivior PLC's 2024 10-K filing highlights its focus on substance use disorder treatments, particularly SUBLOCADE, while addressing ongoing litigation, competitive pressures, and regulatory compliance.

Worse than expected

Summary

Indivior PLC's 2024 10-K filing outlines its business, focusing on developing medicines for substance use disorders (SUDs), particularly opioid use disorder (OUD).
The company's key products include SUBLOCADE, SUBOXONE Film, and OPVEE, with a significant portion of revenue originating from the U.S. market (85% in 2024).
Indivior faces competition from generic products and branded alternatives, impacting market share and pricing.
The company is involved in ongoing litigation, including opioid-related lawsuits and antitrust claims, requiring significant financial resources.
Indivior is committed to complying with legal and regulatory settlements, including a Corporate Integrity Agreement (CIA) and a Resolution Agreement with the DOJ.
The company is investing in research and development, with pipeline products including INDV-2000 and INDV-6001, targeting OUD.
In July 2024, Indivior discontinued marketing and promotion of PERSERIS due to market changes.
The company transitioned its primary stock exchange listing to Nasdaq from the London Stock Exchange in June 2024.
Indivior's net revenue increased by 9% to $1,188 million in 2024, driven by SUBLOCADE volume growth.
The company expects a decline in net revenue and operating income in 2025 due to increased competition and other factors.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's growth in SUBLOCADE sales and a focus on addressing the opioid crisis, the company faces significant legal challenges, increasing competition, and an expected decline in revenue for the coming year.

Positives

Net revenue increased by 9% to $1,188 million in 2024.
SUBLOCADE volume growth continues to drive revenue.
The company is developing new treatments for OUD.
The company is committed to complying with legal and regulatory requirements.
FDA approved label changes for SUBLOCADE including a rapid initiation protocol and alternative injection sites.

Negatives

The company expects a decline in net revenue and operating income in 2025.
Indivior faces increasing competition from generic products and branded alternatives.
The company is involved in ongoing litigation, requiring significant financial resources.
In July 2024, Indivior discontinued marketing and promotion of PERSERIS due to market changes.

Risks

Substantial litigation could cause significant legal expenses and divert management's attention.
Reliance on third parties for manufacturing and clinical trials poses risks to product supply and development.
Failure to comply with legal and regulatory settlements could result in penalties or exclusion from government healthcare programs.
Competition from generic products and branded alternatives could impact market share and pricing.
Uncertainties related to the development of new products and the regulatory approval process.
Dependence on third-party payors for reimbursement of products.
Macroeconomic trends and global developments such as pandemics could adversely affect the business.

Future Outlook

Indivior expects a decline in net revenue and operating income in 2025 due to increased competition and other factors.

Management Comments

Indivior believes the elimination of these requirements as part of this legislation will help to normalize the view of addiction as a chronic brain disease and expand access to evidence-based buprenorphine treatment.
The Company supports efforts to encourage more HCPs to provide medication for OUD.
The Company expects to complete our obligations under the CIA later this year.

Industry Context

The document provides context on the global substance use disorder crisis, the prevalence of opioid use disorder, and the importance of medication-assisted treatment (MAT).

Comparison to Industry Standards

The document mentions Camurus's BRIXADI as a competitor to SUBLOCADE.
It also notes competition from generic naloxone nasal sprays, including Narcan, to OPVEE.
The document references IQVIA data for treatment statistics in Canada.
The document references the European Union Drugs Agency European Drug Report 2024 for opioid use statistics in Europe.
The document references the Australian Institute of Health and Welfare for pharmacotherapy treatment statistics in Australia.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Mark Crossley	Joe Ciaffoni	May 2025 (expected)	Mutual agreement for Mark Crossley to step down.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Appointment of Robert Schriesheim, Joe Ciaffoni, and Daniel Ninivaggi as independent non-executive directors.	December 2024 and January 2025	Increases the number of independent directors and adds expertise in corporate transformation and specialty pharmaceuticals.
Committee Membership	Appointment of Robert Schriesheim and Joe Ciaffoni as members of the Nomination Committee and the Operational Committee.	December 2024	Adds expertise to key committees.
Corporate Governance Guidelines	Adoption of new Corporate Governance Guidelines and Board Committee Charters.	January 1, 2025	Aligns with U.S. practices and provides a framework for Board responsibilities.

Legal Proceedings

The company is involved in ongoing litigation, including opioid-related lawsuits and antitrust claims.
The company has been named as a defendant in numerous lawsuits alleging that SUBOXONE Film was defectively designed and caused dental injury.
Certain shareholders have issued representative and multiparty claims against Indivior PLC in the High Court of Justice for the Business and Property Courts of England and Wales.
An amended purported securities class action lawsuit was filed against Indivior PLC, Mark Crossley, Ryan Preblick, and Richard Simkin on December 5, 2024, alleging violations of certain U.S. federal securities laws.

Related Party Transactions

The company entered into a Relationship Agreement with Oaktree Value Opportunities Fund, L.P., Oaktree London Liquid Value Opportunities Fund (VOF), L.P., Oaktree Phoenix Investment Fund, L.P. and Boston Patriot Arlington ST LLC on December 16, 2024.

Stakeholder Impact

Shareholders may be impacted by the company's financial performance, litigation outcomes, and strategic decisions.
Employees may be impacted by changes in compensation, benefits, and employment terms.
Patients may be impacted by the availability and accessibility of Indivior's products.
Customers may be impacted by changes in pricing and distribution channels.
Suppliers may be impacted by changes in manufacturing and supply chain arrangements.
Creditors may be impacted by the company's ability to service its debt.

Next Steps

Complete obligations under the Corporate Integrity Agreement (CIA) later this year.
Continue to comply with reporting obligations under the Resolution Agreement with DOJ and the stipulated injunction with the FTC.
Continue to comply with reporting obligations under the Settlement Order with the Attorneys General of 41 States and the District of Columbia.
Complete a multiple dose clinical Phase 2 Pharmacokinetic study for INDV-6001 by the end of 2025.
Complete a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with OUD by the end of 2025.
Potentially begin manufacturing SUBLOCADE at the Raleigh Manufacturing Facility in 2026.
Potentially begin realizing cost savings in 2027 from the Raleigh Manufacturing Facility.

Key Dates

Date	Description
1966	RB led the breakthrough discovery of buprenorphine.
1995	SUBUTEX Tablet was first approved for the treatment of opioid dependence in France.
February 1996	SUBUTEX Tablet was launched in France.
2000	The Drug Addiction and Treatment Act of 2000 (DATA 2000) was enacted in the U.S.
October 2002	SUBUTEX Tablet and SUBOXONE Tablet were approved in the U.S. by the FDA.
2003	Sales of SUBUTEX Tablet and SUBOXONE Tablet were launched in the U.S.
September 2006	SUBOXONE Tablet was approved across the EU by the EMA.
August 2010	SUBOXONE Film was approved by the FDA.
2010	Generic versions of SUBUTEX Tablets became available in Europe.
2011	Indivior discontinued the U.S. distribution of SUBUTEX Tablets.
2013	Indivior discontinued distribution of SUBOXONE Tablets in the U.S.
December 23, 2014	The Demerger of Indivior PLC from Reckitt Benckiser Group PLC was effective.
September 2015	The FDA approved the buccal route of administration for SUBOXONE Sublingual Film.
2018	Generic versions of SUBOXONE Tablets became available in Europe.
2018	The FDA approved PERSERIS as a treatment for schizophrenia.
2018	Indivior launched sales of SUBLOCADE in the U.S.
2019	Indivior launched commercial sales of PERSERIS in the U.S.
April 2019	An indictment was brought against Indivior by a grand jury in the Western District of Virginia.
July 2020	Indivior reached agreements with the DOJ, FTC, and state attorneys general to resolve potential criminal and civil liability.
July 24, 2020	Resolution Agreement made with DOJ.
November 20, 2020	FTC Order entered in the United States District Court for the Western District of Virginia.
December 2022	Congress enacted the Mainstreaming Addiction Treatment Act (MAT Act).
March 2, 2023	Indivior completed its acquisition of Opiant Pharmaceuticals, Inc.
May 2023	The FDA approved OPVEE (nalmefene) nasal spray for opioid overdose reversal.
September 2023	Indivior was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
October 2023	Indivior began marketing OPVEE in the U.S.
November 2023	Indivior purchased a manufacturing facility in Raleigh, NC.
July 9, 2024	Indivior announced it would immediately cease all promotion and marketing activities related to PERSERIS.
June 27, 2024	Indivior transitioned its primary stock exchange listing to Nasdaq from the London Stock Exchange.
February 24, 2025	The FDA approved label changes for SUBLOCADE including a rapid initiation protocol and alternative injection sites.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.